THE AMENDMENTS

In The Claims:

- 1-44. (Cancelled)
- 45. (Currently Amended) [[A]] <u>An isolated</u> fragment peptide eomprising consisting of a fragment of the <u>a</u> frameshift polypeptide according to Claim 44, selected from the group consisting of TAF1b (-1) ORF, SEQ ID NO: 20; TAF1b (+1) ORF, SEQ ID NO: 21; HT001 (-1) ORF, SEQ ID NO: 2; HT001 (+1) ORF, SEQ ID NO: 3; and HT001 (-2) ORF, SEQ ID NO: 118; wherein said fragment peptide comprises at least 3 amino acids of a mutated part of the frameshift polypeptide and has a length of at least 15 amino acids.
- 46. (Previously Presented) The fragment peptide according to Claim 45, wherein said fragment peptide has an immunogenic portion with a length of about 10-20 amino acids.
- 47. (Currently Amended) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has the amino acid sequence of SEQ ID NO: 20 and the three amino acids are TIL.
- 48. (Withdrawn-Currently Amended) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has the amino acid sequence of SEQ ID NO: 21 and the three amino acids are KQY.
- 49. (Withdrawn-Currently Amended) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has the amino acid sequence of SEQ ID NO: 2 and the three amino acids are GRR.
- 50. (Withdrawn-Currently Amended) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has the amino acid sequence of SEQ ID NO: 3 and the three amino acids are KAE.

- 51. (Cancelled)
- 52. (Previously Presented) A pharmaceutical composition comprising the fragment peptide according to Claim 45 and a physiologically acceptable carrier.
- 53. (Previously Presented) A pharmaceutical composition comprising the fragment peptide according to Claim 47 and a physiologically acceptable carrier.
- 54. (Withdrawn) A pharmaceutical composition comprising the fragment peptide according to Claim 48 and a physiologically acceptable carrier.
- 55. (Withdrawn) A pharmaceutical composition comprising the fragment peptide according to Claim 49 and a physiologically acceptable carrier.
- 56. (Withdrawn) A pharmaceutical composition comprising the fragment peptide according to Claim 50 and a physiologically acceptable carrier.
- 57. (Cancelled)
- 58. (Previously Presented) A diagnostic kit comprising the fragment peptide according to Claim 45 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.
- 59. (Previously Presented) A diagnostic kit comprising the fragment peptide according to Claim 47 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.
- 60. (Withdrawn) A diagnostic kit comprising the fragment peptide according to Claim 48 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and

additional reagents and buffers for carrying out the detection reactions.

- 61. (Withdrawn) A diagnostic kit comprising the fragment peptide according to Claim 49 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.
- 62. (Withdrawn) A diagnostic kit comprising the fragment peptide according to Claim 50 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.

63-79. (Cancelled)

- 80. (New) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has the amino acid sequence of SEQ ID NO: 118 and the three amino acids are AEE.
- 81. (New) A pharmaceutical composition comprising the fragment peptide according to Claim 80 and a physiologically acceptable carrier.
- 82. (New) A diagnostic kit comprising the fragment peptide according to Claim 80 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.